Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 4

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 3
Chunk 4
---
 a material adverse effect on our bu...  
  Our employees and independent contractors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.                                  
  International expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks.                                                                     

Risks Related to Ownership of Our Common Shares

  We may be or may become classified as a passive foreign investment company.  
 ───────────────────────────────────────────────────────────────────────────────

  As a foreign private issuer, we are permitted, and intend, to follow certain home country corporate governance practices and we will not be subject to certain U. S. securities laws.  

  We are an emerging growth company and the reduced disclosure requirements applicable to emerging growth companies may make our Common Shares less attractive to investors.  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, our shareho...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Risks Related to our Location in Israel and our International
Operations

  Part of our operations are conducted in Israel. Conditions in Israel, including the recent attack by Hamas and other terrorist organizations and Israel’s war against them, may affect our operat...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Because we are incorporated in British Columbia and some of our directors and officers are in Canada, it may be difficult for U. S. investors to enforce civil liabilities. Similarly, it may be ...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Operating outside of the United States presents specific risks to our business.  

Risks Related to Our Financial Condition and
Capital Requirements

We have incurred losses since our inception. We anticipate that
we will incur significant losses for the foreseeable future, and we may never achieve or maintain profitability.

We are a clinical pharmaceutical company. We have
incurred operating losses each year since our inception, including operating losses of $ 5,744,925, $6,303,434 and